372 related articles for article (PubMed ID: 18300112)
1. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
[TBL] [Abstract][Full Text] [Related]
2. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
Goral S; Ynares C; Dummer S; Helderman JH
Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
[TBL] [Abstract][Full Text] [Related]
3. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
[TBL] [Abstract][Full Text] [Related]
4. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.
Balfour HH; Chace BA; Stapleton JT; Simmons RL; Fryd DS
N Engl J Med; 1989 May; 320(21):1381-7. PubMed ID: 2541335
[TBL] [Abstract][Full Text] [Related]
8. Adverse neuropsychiatric effects of cytomegalovirus prophylaxis with valaciclovir in renal transplant recipients.
Das V; Peraldi MN; Legendre C
Nephrol Dial Transplant; 2006 May; 21(5):1395-401. PubMed ID: 16401626
[TBL] [Abstract][Full Text] [Related]
9. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.
Sund F; Tufveson G; Döhler B; Opelz G; Eriksson BM
Nephrol Dial Transplant; 2013 Mar; 28(3):758-65. PubMed ID: 23243043
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus disease in renal transplant recipients: a single-center experience.
Basri N; Abdullah KA; Shaheen FA
Exp Clin Transplant; 2007 Jun; 5(1):601-3. PubMed ID: 17617050
[TBL] [Abstract][Full Text] [Related]
13. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients.
Stratta RJ; Alloway RR; Lo A; Hodge EE;
Transplant Proc; 2004 May; 36(4):1082-3. PubMed ID: 15194376
[TBL] [Abstract][Full Text] [Related]
14. Aciclovir or ganciclovir universal prophylaxis of cytomegalovirus infection in liver transplantation: an economic analysis.
Leong RW; Smith DW; Garas G; Beaman JM; Mitchell AW; Heath DI; House AK; Jeffrey GP
Intern Med J; 2004 Jul; 34(7):410-5. PubMed ID: 15271175
[TBL] [Abstract][Full Text] [Related]
15. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
16. Pancreas transplant outcomes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR).
Gruessner AC; Sutherland DE
Clin Transpl; 2008; ():45-56. PubMed ID: 19708445
[TBL] [Abstract][Full Text] [Related]
17. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients.
Leroy F; Sechet A; Abou Ayache R; Thierry A; Belmouaz S; Desport E; Bauwens M; Bridoux F; Touchard G
Transplant Proc; 2006 Sep; 38(7):2324-6. PubMed ID: 16980080
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus prevention and long-term recipient and graft survival in pediatric heart transplant recipients.
Snydman DR; Kistler KD; Ulsh P; Morris J
Transplantation; 2010 Dec; 90(12):1432-8. PubMed ID: 21076378
[TBL] [Abstract][Full Text] [Related]
20. Kidney transplantation in the United States.
Cecka JM
Clin Transpl; 2008; ():1-18. PubMed ID: 19711510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
